In a pig model of coronary artery disease, oral semaglutide improved left ventricular function, increased blood flow to ischemic heart muscle, and reduced fibrosis through AMPK-mediated endothelial protection.
Improved perfusion to ischemic heartOral semaglutide significantly increased blood flow to the most oxygen-starved heart muscle (p<0.03) while reducing fibrosis and improving pump function in pigs with coronary artery disease
What the researchers found
Semaglutide improved left ventricular ejection fraction at rest and during rapid pacing (both p<0.03), increased perfusion to the most ischemic myocardium at rest and during pacing (both p<0.03), reduced perivascular and interstitial fibrosis (both p<0.03), and decreased apoptosis (p=0.008). Mechanism: increased AMPK activation (p=0.005) with downstream eNOS upregulation (p=0.014).
Why it matters
This is the first study showing oral semaglutide directly improves heart function in coronary artery disease — in a large animal model without diabetes or obesity. It suggests semaglutide's cardiovascular benefits aren't just from metabolic improvement but from direct cardiac effects, potentially offering hope for patients with refractory angina who have no other options.
The numbers in context
Coronary artery disease is the leading cause of death worldwide. Up to 1/3 of patients have residual angina despite optimal therapy.
How the study worked
Randomized controlled animal study. 17 Yorkshire swine received ameroid constrictors on the left circumflex coronary artery. Treatment group (n=8): oral semaglutide 1.5→3 mg over 5 weeks. Control group (n=9): no drug. Cardiac function measured by pressure-volume loop catheterization, perfusion by microsphere injection. Tissue analysis by immunoblotting, immunohistochemistry, and immunofluorescence.
Who was studied
Large animal model of coronary artery disease
What this study cannot tell us
Preprint (bioRxiv) — not yet peer reviewed. Relatively small group sizes (8-9 per group). Short treatment duration (5 weeks). Ameroid constrictor model creates gradual stenosis that may not fully replicate human coronary disease. Oral semaglutide doses may not be directly comparable to human doses. No long-term follow-up data.
How to read the evidence
Preliminary evidence from a well-designed large animal study, but currently a preprint (not peer reviewed). Yorkshire swine are among the most translationally relevant cardiac models.
When this study was published
Posted as preprint in 2024. Peer review status should be checked for the most current evaluation.
The bigger picture
The cardiovascular outcome trials for GLP-1 drugs showed clear benefits, but couldn't determine whether the heart protection was direct or secondary to metabolic improvements. This study provides strong evidence for a direct cardiac effect — semaglutide actually improves blood flow and reduces scarring in ischemic hearts, independent of diabetes or weight loss.
Questions still open
- Would semaglutide benefit patients with refractory angina who can't undergo procedures?
- Is the AMPK-eNOS mechanism also responsible for semaglutide's cardiovascular benefits in human clinical trials?
Common questions
Does this mean semaglutide can treat heart disease directly?
What is the AMPK pathway and why does it matter here?
Read the original research
Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease.
bioRxiv : the preprint server for biology
Citation
Stone, Christopher R; Harris, Dwight D; Broadwin, Mark; Kanuparthy, Meghamsh; Nho, Ju-Woo; Yalamanchili, Keertana; Hamze, Jad; Abid, M Ruhul; Sellke, Frank W. (2024). Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease.. bioRxiv : the preprint server for biology. https://doi.org/10.1101/2024.08.15.608191